Inhibrx Biosciences, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Inhibrx announced Phase 2 HexAgon trial results for INBRX-106 (OX40 agonist) + pembrolizumab in head-and-neck cancer (HNSCC): 48.3% confirmed objective response rate (cORR) vs 26.5% for pembrolizumab alone in 63 evaluable patients; median PFS 9.6 months vs 4.9 months; HPV+ subgroup (n=19) showed 80% cORR vs 33% and 90% six-month PFS vs 33%. Company will expand Phase 2 by ~50 HPV+ patients, targeting potential accelerated approval by end-2028/early-2029. Safety profile manageable (rash, fatigue, diarrhea mostly grade 1-2).
Why this rating
Clinically meaningful efficacy data in small but meaningful trial; HPV+ signal is transformational for ~$174M market-cap biotech. Accelerated approval pathway real. Phase 3 confirmatory study planned. Expansion opportunity into $50B+ immunogenic tumor markets adds optionality, but lead program still Phase 2.
Tradability signal
NO TRADE
No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -1.29% over 4 hrs, n=19).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $114.34 ▲ 0.00% | at our read · unknown $114.34 | +10 min · unknown $114.34 ▲ 0.00% | +30 min · unknown $114.34 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.